期刊文献+

hTPO和hNIS共转染胶质瘤细胞碘摄取和^131I治疗的实验研究

Radioiodide uptake and therapy of glioma cells mediated by co - transfection of human sodium iodide sympoter gene and thyroperoxidase gene
下载PDF
导出
摘要 目的构建含有人甲状腺过氧化物酶基因(hTPO)的重组腺病毒,并与人钠-碘转运体基因(hNIS)共转染至神经胶质瘤细胞中,研究其摄碘能力及对肿瘤细胞的杀伤能力,探讨131I治疗胶质瘤的可能性。方法应用AdEasy系统构建重组腺病毒AdTPO,利用重组质粒将hNIS基因转染入神经胶质瘤细胞系U251中获得hNIS—U251细胞系作为阴性对照组,再利用重组腺病毒AdTPO将TPO基因转染入hNIS—U251细胞系中获得AdTPO—hNIS—U251作为实验组,未转入hTPO和hNIS的细胞U251作为空白对照组。研究三组细胞的摄碘实验、过氯酸盐抑制实验、有机化测定实验检测其摄碘功能,细胞克隆形成实验评价131I对转染肿瘤的杀伤作用。结果成功构建出重组腺病毒AdTPO,并在稳定表达hNIS的U251细胞中实现了hTPO的共转染。hNIS—U251组(每分钟放射性计数55769.96±4353.26)比空白对照组(每分钟放射性计数507.67±57.69)摄碘能力增高约110倍,有效半衰期7分钟,有机化程度约为0.1%,细胞克隆形成率(9.08±2.86)%,较对照组减低约10倍。AdTPO—hNIS—U251组(每分钟放射性计数74647.53±3605.88)比空白对照组摄碘能力增高约147倍,有效半衰期延长至13分钟,有机化程度增高至10%,细胞克隆形成率(6.80±2.09)%,较对照组减低约13倍。结论将hTPO和hNIS共转染至神经胶质瘤细胞后,可有效提高细胞的摄碘能力,hTPO延长了放射性碘在细胞中的停留时间,131I对瘤细胞有较强的杀伤作用。 Objective Construct a recombinant adenovirus containing the human hydroperoxidase (hT- PO) gene, transfer the hTPO genes and human sodium/iodide symporter(hNIS) gene into glioma cells and study the iodide uptake ability of the cells and the killing effect of radioiodine, so as to investigate the feasibility of radioiodine therapy on glioma. Methods The recombinant adenovirus AdTPO was constructed by AdEasy system. Tranfecting hNIS gene into human glioma cell line U251 through recombinant plasmid, the stably expressing hNIS gene cell line hNIS - U251 was determined as negative control group. Then hTPO gene was transfected into hNIS - U251 by recombinant adenovirus AdTPO, achieving AdTPO - hNIS - U251, determined as testing group. U251 cell line without hNIS or hTPO gene was applied as control group. We investigated the iodide uptake assay, perchlorate suppressive assay, iodide organification assay to confirm gene expression and function. Killing effect of radioiodide on tumor cells was studied by clonogenic assay in vitro. Results Recombinant adenovirus AdTPO was correctly constructed, we were successful in co - transfecting hTPO gene into stably expressing hNIS cell line ( hNIS - U251 ), obtaining AdTPO - hNIS - U251. In hNIS - U251 group, the iodide uptake ability (55769.96±4353.26 count · min-i ) was 110 folds higher than that in control group(507.67± 57.69 count · min -i ) ,the effective half - life time was 7 minutes, the organification percentage was 0.1%, and the rate of clonal forming was (9.08 ± 2.86) % , that was 10 folds lower compared with control group. While in AdTPO - hNIS - U251 group, the iodide uptake ability(74647.53 + 3605.88 count · min- 1 )was 147 folds higher than that in control group, the effective half-life time prolonged to 13 minutes, the organification percentage reached to 10%, and the rate of clonal forming was (6.80 + 2.09) %, which was 13 folds lower than control group respectively. Conclusion By co - transfection of hTPO and hNIS genes into glioma cell line U251, the iodide uptake ability increased markedly, hTPO increased the retension of iodide in the cells, and the 131I could kill tumor cells effectively.
出处 《实用肿瘤学杂志》 CAS 2011年第3期201-206,共6页 Practical Oncology Journal
基金 天津市卫生局科技基金(05KYZ83)
关键词 人钠-碘转运体 甲状腺过氧化物酶 重组腺病毒 放射性碘治疗 神经胶质瘤 Human sodium/ iodide symporter Thyroperoxidase Recombinant adenovirus Radioiodine therapy Glioma
  • 相关文献

参考文献8

  • 1Zawroeki A, Biernat W. Epidermal growth factor receptor in glioblastoma [ J ]. Folia Neuropathol, 2005,43 : 123 - 132.
  • 2谭建,李玮,刘晓华,肖茜,贾强,李宁.人钠/碘同向转运体基因转染胶质瘤细胞介导放射性碘治疗的研究[J].中华核医学杂志,2008,28(2):79-83. 被引量:8
  • 3Dadachova E, Carrasco N. The Na/l symporter (NIS) : ima- ging and therapeutic applications [ J ]. Semin Nucl Med,2004,34( 1 ) :23 -31.
  • 4Faivre J, Clerc J, Gerolami R, et al. Long - term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats [ J ]. Cancer Res, 2004,64(21 ) :8045 - 8051.
  • 5Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue - specific sodium iodide sym- porter gene transfer [ J ]. Gene Ther, 2005,12 ( 3 ) : 272 - 280.
  • 6Chen L, Altmann A, Mier W, et al. Radioiodine therapy ofhematoma using targeted transfer of the human sodium/io- dide symporter gene [ J ]. J Nucl Med, 2006,47 ( 5 ) : 854 - 862.
  • 7Haberkorn U, Kinscherf R, Kissel M, et al. Enhanced iodide transport after transfer of the human sodium iodide symport- er gene is associated with lack of retention and low absorbed dose [ J ]. Gene Ther,2003,10 (9) :774 - 780.
  • 8St George JA. Gene therapy progress and prospects:adenovi- ral vectors[J]. Gene Ther,2003 ,10(14) :1135 -1141.

二级参考文献12

  • 1张一帆,李彪,赵龙,尤蓓,尹桂芝,贾世海,朱承谟.杆状病毒介导NIS基因放射治疗甲状腺癌的实验研究[J].中华核医学杂志,2004,24(5):264-267. 被引量:6
  • 2Zawrocki A, Biemat W. Epidermal growth factor receptor in glioblastoma. Folia Neuropathol, 2005,43 : 123-132.
  • 3Gaut AW, Niu G, Krager KJ, et al. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck, 2004, 26 : 265-271 .
  • 4Lee YJ,Chung JK,Shin JH, et al. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid, 2004, 14: 889-895.
  • 5Petrich T, Knopp WH, Potter El. Functional activity of human sodium/iodide symporter in tumor cell Lines. Nuklearmedizin, 2003, 42: 8-15.
  • 6Dadachova E, Carrasco N. The Na/Ⅰ symperter ( NIS ) : imaging and therapeutic applications. Semin Nucl Med, 2004, 34: 23-31.
  • 7Wapnir IL, van de Rijn M, Nowels K,et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue mieroarrays and conventional sections. J Clin Endocrinol Metab, 2003, 88: 1880-1888.
  • 8Spitaweg C, Morris JC. Gene therapy for thyroid cancer: current status and future prospects. Thyroid, 2004, 14: 424-434.
  • 9Faivre J, Clere J, Gerolami R, et al . Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res, 2004, 64: 8645-8051.
  • 10Dwyer RM,Bergert ER,O'connor MK,et al. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res, 2005,11: 1483-1489.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部